These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 32322204)

  • 1. Olinciguat, an Oral sGC Stimulator, Exhibits Diverse Pharmacology Across Preclinical Models of Cardiovascular, Metabolic, Renal, and Inflammatory Disease.
    Zimmer DP; Shea CM; Tobin JV; Tchernychev B; Germano P; Sykes K; Banijamali AR; Jacobson S; Bernier SG; Sarno R; Carvalho A; Chien YT; Graul R; Buys ES; Jones JE; Wakefield JD; Price GM; Chickering JG; Milne GT; Currie MG; Masferrer JL
    Front Pharmacol; 2020; 11():419. PubMed ID: 32322204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological Characterization of IW-1973, a Novel Soluble Guanylate Cyclase Stimulator with Extensive Tissue Distribution, Antihypertensive, Anti-Inflammatory, and Antifibrotic Effects in Preclinical Models of Disease.
    Tobin JV; Zimmer DP; Shea C; Germano P; Bernier SG; Liu G; Long K; Miyashiro J; Ranganath S; Jacobson S; Tang K; Im GJ; Sheppeck J; Moore JD; Sykes K; Wakefield J; Sarno R; Banijamali AR; Profy AT; Milne GT; Currie MG; Masferrer JL
    J Pharmacol Exp Ther; 2018 Jun; 365(3):664-675. PubMed ID: 29643251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Olinciguat, a stimulator of soluble guanylyl cyclase, attenuates inflammation, vaso-occlusion and nephropathy in mouse models of sickle cell disease.
    Tchernychev B; Li H; Lee SK; Gao X; Ramanarasimhaiah R; Liu G; Hall KC; Bernier SG; Jones JE; Feil S; Feil R; Buys ES; Graul RM; Frenette PS; Masferrer JL
    Br J Pharmacol; 2021 Sep; 178(17):3463-3475. PubMed ID: 33864386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery and development of next generation sGC stimulators with diverse multidimensional pharmacology and broad therapeutic potential.
    Buys ES; Zimmer DP; Chickering J; Graul R; Chien YT; Profy A; Hadcock JR; Masferrer JL; Milne GT
    Nitric Oxide; 2018 Aug; 78():72-80. PubMed ID: 29859918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble guanylate cyclase stimulator praliciguat attenuates inflammation, fibrosis, and end-organ damage in the Dahl model of cardiorenal failure.
    Shea CM; Price GM; Liu G; Sarno R; Buys ES; Currie MG; Masferrer JL
    Am J Physiol Renal Physiol; 2020 Jan; 318(1):F148-F159. PubMed ID: 31608671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble guanylate cyclase stimulators in pulmonary hypertension.
    Stasch JP; Evgenov OV
    Handb Exp Pharmacol; 2013; 218():279-313. PubMed ID: 24092345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble Guanylate Cyclase Stimulators and Activators: Where are We and Where to Go?
    Xiao S; Li Q; Hu L; Yu Z; Yang J; Chang Q; Chen Z; Hu G
    Mini Rev Med Chem; 2019; 19(18):1544-1557. PubMed ID: 31362687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The CNS-Penetrant Soluble Guanylate Cyclase Stimulator CY6463 Reveals its Therapeutic Potential in Neurodegenerative Diseases.
    Correia SS; Iyengar RR; Germano P; Tang K; Bernier SG; Schwartzkopf CD; Tobin J; Lee TW; Liu G; Jacobson S; Carvalho A; Rennie GR; Jung J; Renhowe PA; Lonie E; Winrow CJ; Hadcock JR; Jones JE; Currie MG
    Front Pharmacol; 2021; 12():656561. PubMed ID: 34108877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models.
    Sharkovska Y; Kalk P; Lawrenz B; Godes M; Hoffmann LS; Wellkisch K; Geschka S; Relle K; Hocher B; Stasch JP
    J Hypertens; 2010 Aug; 28(8):1666-75. PubMed ID: 20613628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel sGC Stimulators and sGC Activators for the Treatment of Heart Failure.
    Breitenstein S; Roessig L; Sandner P; Lewis KS
    Handb Exp Pharmacol; 2017; 243():225-247. PubMed ID: 27900610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of 5-cyclopropyl-2-[1-(2-fluoro-benzyl)-1H-pyrazolo[3,4-b]pyridine-3-yl]pyrimidin-4-ylamine (BAY 41-2272) on smooth muscle tone, soluble guanylyl cyclase activity, and NADPH oxidase activity/expression in corpus cavernosum from wild-type, neuronal, and endothelial nitric-oxide synthase null mice.
    Teixeira CE; Priviero FB; Webb RC
    J Pharmacol Exp Ther; 2007 Sep; 322(3):1093-102. PubMed ID: 17596536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The soluble guanylate cyclase stimulator riociguat and the soluble guanylate cyclase activator cinaciguat exert no direct effects on contractility and relaxation of cardiac myocytes from normal rats.
    Reinke Y; Gross S; Eckerle LG; Hertrich I; Busch M; Busch R; Riad A; Rauch BH; Stasch JP; Dörr M; Felix SB
    Eur J Pharmacol; 2015 Nov; 767():1-9. PubMed ID: 26407652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-fibrotic effects of soluble guanylate cyclase stimulators and activators: A review of the preclinical evidence.
    Sandner P; Stasch JP
    Respir Med; 2017 Jan; 122 Suppl 1():S1-S9. PubMed ID: 28341058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of YC-1, an NO-independent, superoxide-sensitive stimulator of soluble guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators.
    Mülsch A; Bauersachs J; Schäfer A; Stasch JP; Kast R; Busse R
    Br J Pharmacol; 1997 Feb; 120(4):681-9. PubMed ID: 9051308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soluble guanylyl cyclase (sGC) degradation and impairment of nitric oxide-mediated responses in urethra from obese mice: reversal by the sGC activator BAY 60-2770.
    Alexandre EC; Leiria LO; Silva FH; Mendes-Silvério CB; Calmasini FB; Davel AP; Mónica FZ; De Nucci G; Antunes E
    J Pharmacol Exp Ther; 2014 Apr; 349(1):2-9. PubMed ID: 24421320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease.
    Boerrigter G; Burnett JC
    Cardiovasc Drug Rev; 2007; 25(1):30-45. PubMed ID: 17445086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological characterisation of the relaxation induced by the soluble guanylate cyclase activator, BAY 60-2770 in rabbit corpus cavernosum.
    Estancial CS; Rodrigues RL; De Nucci G; Antunes E; Mónica FZ
    BJU Int; 2015 Oct; 116(4):657-64. PubMed ID: 25715977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Potential of sGC Modulators for the Treatment of Age-Related Fibrosis: A Mini-Review.
    Sandner P; Berger P; Zenzmaier C
    Gerontology; 2017; 63(3):216-227. PubMed ID: 27784018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble guanylate cyclase stimulators and their potential use: a patent review.
    Sandner P; Vakalopoulos A; Hahn MG; Stasch JP; Follmann M
    Expert Opin Ther Pat; 2021 Mar; 31(3):203-222. PubMed ID: 33395323
    [No Abstract]   [Full Text] [Related]  

  • 20. Activators and stimulators of soluble guanylate cyclase counteract myofibroblast differentiation of prostatic and dermal stromal cells.
    Zenzmaier C; Kern J; Heitz M; Plas E; Zwerschke W; Mattesich M; Sandner P; Berger P
    Exp Cell Res; 2015 Nov; 338(2):162-9. PubMed ID: 26410556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.